Screener
Crinetics Pharmaceuticals CRNX Preferred Stock Par Value Per Share
Preferred Stock Par Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| TOTAL LIABILITIES | 120,677 | 134,174 |
| Commitments and contingencies (Note 6) | ||
| STOCKHOLDERS’ EQUITY | ||
| Preferred stock, $0.001 par; 10,000 shares authorized; no shares issued or outstanding at March 31, 2026 or December 31, 2025 | — | — |
| Common stock and paid-in capital, $0.001 par; 200,000 shares authorized; 105,314 shares issued and outstanding at March 31, 2026; 95,575 shares issued and outstanding at December 31, 2025 | 2,828,204 | 2,407,757 |
| Accumulated other comprehensive (loss) income | (1,254) | 1,865 |
| Accumulated deficit | (1,545,272) | (1,417,427) |
| Stock held in trust | (1,032) | (112) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's preferred stock par value per share?
- Crinetics Pharmaceuticals (CRNX) reported preferred stock par value per share of $0.00 in Q1 2026.
- What does preferred stock par value per share mean?
- The par value per share of preferred stock is a nominal value assigned to preferred shares for accounting and legal purposes. It does not reflect the market value or the liquidation preference of the stock. It is primarily a regulatory and historical accounting figure.
Ask your AI about Crinetics Pharmaceuticals's preferred stock par value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude